DEA Ban on a Fan-Favorite Drug Puts Opioid Research at Risk

The Drug Enforcement Administration has banned a drug that some people struggling with opioid use had described as a miracle. The agency placed it in Schedule I, the most restrictive category under federal law, which is reserved for substances the government considers to have a high potential for abuse and no accepted medical use.

Researchers say the decision could do more than limit access for users. Working with a Schedule I substance requires special federal registration and approval, and that process is slow and demanding. Scientists warn that the ban could effectively stop studies that were examining the drug as a promising opioid treatment, just as the field was beginning to build evidence around it.

The available details are limited. The source material does not name the drug, quote the researchers in full, or say whether the DEA plans any exemptions for ongoing work. Those answers will determine how far the impact reaches, for patients who had turned to the drug on their own and for the research teams who hoped to test it more rigorously.

For now, the decision leaves a difficult gap. Users who saw the drug as a lifeline lose a option they had found on their own, and researchers lose a path to find out whether its benefits hold up under controlled conditions.